Case Western Reserve University with Copernicus Therapeutics, Inc. and Polgenix Receive $3.9 Million from the Ohio Biomedical Research Commercialization Program (BRCP)
CLEVELAND--(BUSINESS WIRE)--Case Western Reserve University School of Medicine, in collaboration with Copernicus Therapeutics, Inc. and Polgenix, Inc., was selected to receive $3.9 million in funding from the Ohio Biomedical Research Commercialization Program (BRCP) as awarded by Lieutenant Governor Lee Fisher, Chair of the Ohio Third Frontier Commission.